Baseline characteristics | HSD - Italy | IPCI - UK | SIDIAP - Spain | THIN - UK | Total population | |||||
---|---|---|---|---|---|---|---|---|---|---|
NAFLD/NASH | Matched non-NAFLD/NASH | NAFLD/NASH | Matched non-NAFLD/NASH | NAFLD/NASH | Matched non-NAFLD/NASH | NAFLD/NASH | Matched non-NAFLD/NASH | NAFLD/NASH | Matched non-NAFLD/NASH | |
Follow-up years prior to index date: median (IQR) | 7.5 (4.66–10.5) | 7.7 (4.8–10.6) | 2.2 (0.9–3.8) | 2.2 (1–3.8) | 5.2 (3.1–7.1) | 5.2 (3.1–7.1) | 13.4 (5.5–23.4) | 13.9 (5.8–23.4) | 5.4 (2.8–8.0) | 5.5 (2.9–8.3) |
Follow-up years post index date: median (IQR) | 5.3 (2.7–8.1) | 5.2 (2.7–7.9) | 1.8 (0.8–3.2) | 1.8 (0.8–3.3) | 3.5 (1.7–5.6) | 3.5 (1.7–5.7) | 3.1 (1.3–5.9) | 3.0 (1.3–5.7) | 3.3 (1.5–5.8) | 3.2 (1.5–5.7) |
Age in years, mean (SD) | 56.1 (14.4) | 55.0 (13.7) | 56.8 (13.9) | 56.1 (13.5) | 55.9 (13.4) | 54.5 (13.1) | 54.4 (13.4) | 53.5 (13.5) | 55.8 (13.6) | 54.6 (13.3) |
Gender, % of Males | 57.3 | 54.7 | 49.2 | 48.5 | 52.6 | 48.8 | 51.5 | 51.0 | 52.7 | 50.1 |
Current smokers*, % | 11.3 | 9.0 | 17.2 | 11.5 | 17.6 | 15.4 | 17.8 | 19.0 | 16.5 | 14.4 |
Body mass index in kg/m2, mean (SD) | 29.8 (5.0) | 27.5 (5.0) | 30.8 (5.3) | 28.3 (5.2) | 31.4 (5.1) | 28.7 (5.1) | 32.5 (6.0) | 28.5 (5.9) | 31.3 (5.3) | 28.5 (5.3) |
Obesity (%) | 21.5 | 9.0 | 23.6 | 9.0 | 39.5 | 18.1 | 49.6 | 18.2 | 36.0 | 15.4 |
History of type 2 diabetes (%) | 17.6 | 11.0 | 20.4 | 9.2 | 19.9 | 10 | 21.5 | 7.1 | 19.8 | 9.6 |
History of hypertension (%) | 47.2 | 36.6 | 36.0 | 26.2 | 42.6 | 29.3 | 41.2 | 25.9 | 42.2 | 29.6 |
Statin use (%) | 22.0 | 15.8 | 33.2 | 22.0 | 6.9 | 6.8 | 32.6 | 18.5 | 16.9 | 12.1 |
Aspartate transaminase (IU/L), median (IQR) | 24 (19–32) | 20 (17–25) | 29 (22–40) | 23 (20–28) | 29 (22–40) | 22 (18–27) | 31 (23–45) | 22 (19–27) | 28 (21–39) | 21 (18–26) |
Alanine transaminase (IU/L), median (IQR) | 30 (20–48) | 21 (16–29) | 37 (25–55) | 25 (18–33) | 34 (22–53) | 20 (15–28) | 42 (26–65) | 22 (17–31) | 35 (23–54) | 21 (16–29) |